iiinova — where your digital self keeps evolving

Brooke M. Emerling

@bemerling.bsky.social

7 followers 5 following 0 posts

Posts Replies Media

Reposted by Brooke M. Emerling

Cosimo Commisso @cosimocommisso.bsky.social · 02/09/2025

Thrilled to share our first collaboration with @bemerling.bsky.social 🎉 Fantastic work by first author Dr. Gurpreet Arora showing how PI5P4Kα fuels pancreatic cancer cell fitness and reveals a new therapeutic vulnerability. www.cell.com/cell-reports...

PI5P4Kα promotes glucose and iron acquisition to support metabolic fitness in pancreatic cancer

PI5P4Kα is a critical metabolic gatekeeper in PDAC, promoting glucose and iron acquisition to support tumor survival. Arora et al. demonstrate that PI5P4Kα suppression disrupts the metabolic flexibili...

Reposted by Brooke M. Emerling

Cosimo Commisso @cosimocommisso.bsky.social · 21/04/2025

New preprint with @bemerling.bsky.social + first author Dr. Preeti Arora: PI5P4Kα supports pancreatic cancer cell survival by maintaining iron. Knockdown disrupts iron homeostasis, triggers apoptosis, and blocks tumor growth. A potential new target. www.biorxiv.org/content/10.1...

PI5P4Kα Regulates Iron Balance to Promote Metabolic Fitness in Pancreatic Cancer

Phosphoinositide kinases generate distinct phosphoinositides that regulate processes that maintain cellular fitness. Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) have garnered interest for the...

Reposted by Brooke M. Emerling

Nature Reviews Cancer @natrevcancer.nature.com · 16/04/2025

#REVIEW 🚨 Brooke Emerling & Co @sbpdiscovery.bsky.social @bemerling.bsky.social summarize the roles of phosphatidylinositol 4-kinases #PI4Ks and phosphatidylinositol phosphate kinases #PIPKs in cancer. 📖 ⬇️

Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities - Nature Reviews Cancer

In this Review, Emerling and colleagues summarize the roles of phosphatidylinositol 4-kinases (PI4Ks) and phosphatidylinositol phosphate kinases (PIPKs) in cancer. They highlight the altered expression of these kinases in tumours and discuss ongoing efforts in developing therapies targeting these lesser-studied phosphoinositide kinase families.